USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOPEPTIDES, INC.
Address:
18 WOODHULL RD
EAST SETAUKET, NY
Phone:
N/A
URL:
N/A
EIN:
113601189
DUNS:
140704532
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,390,155.00 6
SBIR Phase II $2,926,946.00 2

Award List:

A RAPID IMMUNOASSAY FOR DETECTION OF YERSINIA PATHOGENS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$143,157.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this Fast-Track project is to develop a Rapid-format immunodiagnostic assay capable of quick detection of contamination or infection with Yersinia pathogens, especially biologically engineered pathogens that might be used as weapons of… More

WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERI

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$147,863.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is a significant public health treat, it is the most prevalent vector borne infectious disease in the United States, and its geographical range is expanding. The white-footed mouse is the major natural reservoir of Borrelia burgdorferi, the… More

WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERI

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$860,668.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is a significant public health treat, it is the most prevalent vector borne infectious disease in the United States, and its geographical range is expanding. The white-footed mouse is the major natural reservoir of Borrelia burgdorferi, the… More

Multi-peptide assay for serodiagnosis of Lyme disease

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$599,142.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a more sensitive, specific serologic assay for detection of Lyme disease especially early disease. Lyme disease is the most common vector borne infectious disease in the United States and Europe an d as such it is a significant public health… More

BAIT VACCINE AGAINST LYME BORRELIOSIS

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$599,993.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is caused by the spirochete Borrelia burgdorferi. This zoonosis is the most prevalent vector borne infectious disease in the United States and Europe and it continues to grow geographically. The enzootic cy cle of this pathogen requires that Ixodes… More

Multi-antigen peptide assay for the serodiagnosis of Lyme disease

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,066,278.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lyme Disease (LD) is the most common vector-borne infectious disease in the United States and remains a significant public health concern. The laboratory diagnosis of LD depends on the demonstration of antibodies again st Borrelia burgdorferi. Current serologic… More

Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Maria Gomes-solecki – (917) 741-2470
Abstract:
DESCRIPTION (provided by applicant): Caused by Borrelia burgdorferi, Lyme Disease (LD) can affect the skin, heart, joints or nervous system leading to an array of symptoms that overlap with those of other illnesses. LD is the most common vector-borne infectious disease in the United States and… More

Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Paul M. Arnaboldi – 516-662-3287
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is the most common vector borne infectious disease in North America and Europe. It is a progressive disease with a wide array of clinical manifestations. Treatment of early infection is highly effective, and early diagnosis and treatment are critical… More